Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 5Gastro-enteropancreatic neuroendocrine tumor 2Adenoma, Islet Cell 2Pancreatic Neoplasms 1Neuroblastoma 1Glioblastoma 1

Interventions

lutetium Lu 177 dotatate 2Sunitinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Everolimus 2sargramostim 1sapanisertib 1pentetreotide 1pasireotide 1napabucasin 1montanide ISA 51 1irinotecan sucrosofate 1incomplete Freund's adjuvant 1fludarabine phosphate 1aflibercept 1Taxes 1Sorafenib 1Salts 1Paclitaxel 1Oxaliplatin 1Octreotide 1Leucovorin 1Irinotecan 1Interleukin-13 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Adenoma, Islet Cell × lutetium Lu 177 dotatate × Clear all
NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT06663072 2026-01-09

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

University of Chicago

Phase 1 Recruiting
25 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡